Acute Kidney Injury (AKI) Disease Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Diagnosis (Urine Tests, Blood Tests, Glomerular Filtration Rate (GFR), Imaging Tests, Kidney Biopsy), By Type Of RRT (Continuous, Intermittent), And By Geography - Forecasts From 2022 To 2027

  • Published : Dec 2022
  • Report Code : KSI061612284
  • Pages : 111

The Acute kidney injury disease treatment market is projected to grow at a CAGR of 2.07% during the forecast period to reach US$34.596 billion by 2027, from US$29.976 billion in 2020.

Acute kidney failure is a rapid loss of the kidney’s ability to remove waste and help balance fluids and electrolytes in the body. It is an acute inflammation of the kidney that impairs kidney function. The causes include decreased blood flow, autoimmune kidney disease, urinary tract blockage, blood clotting in kidney blood vessels, and pregnancy complications. The most common test to diagnose acute kidney disease is urine analysis wherein a urine sample is taken by a doctor that studies the physical, microscopic, and chemical appearance of the urine. Dialysis and RRT (Renal Replacement Therapy) are the most common treatments to heal the kidneys. Furthermore, the rise in the number of elderly people is increasing the demand for acute kidney disease treatment.

An increase in the geriatric population is expected to boost the acute kidney injury disease treatment market.

The increase in the elderly population is increasing the risks of chronic diseases as a result of aging, and weakness in the body. As per WHO, the number of people aged 60 years and above outnumbered the number of children in 2020. Additionally, the pace of population aging is much faster than it was in the past owing to unhealthy physical and social environments, poor eating habits, and intake of toxins such as alcohol and tobacco. Moreover, the prevalence of diabetes, high blood pressure, and bladder issues are further increasing the risk for acute kidney disease which is further rising the demand for acute kidney disease treatment via intake of antibiotics, dialysis, and by use of a urinary catheter. As per National Kidney Foundation, more than 80% of patients who receive acute kidney failure treatment belong to affluent countries with universal access to healthcare facilities. As per the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 2 in 1000 Americans are living with end-stage kidney disease with 71% on dialysis and 29% with a kidney transplant. The increase in kidney diseases is further increasing the need for accurate and efficient treatment.

However, the absence of quality healthcare facilities in developing countries and rising medicare costs without insurance or any financial support can hinder the growth of the acute kidney injury disease treatment market.

Product Offerings

  • Acute Kidney Injury Pipeline – by EBI. It is a leading product of the company that prevents tissue damage from fluid overload and is applicable for all conditions that result in fluid overload and hemodynamic instability such as viral infections with lung edema. Moreover, the product is targeted to prevent acute kidney injury. 
  • RenalGuard Therapy®– by Renalguard. Renalguard’s acute kidney injury treatment solutions are intended to use for 14 days of temporary replacement of urine output by infusing a matched volume of a sterile replacement solution that can maintain the patient’s intravascular fluid volume. Furthermore, the device is CE-marked for sale in Europe and other countries of the world.

During the forecast period, North America is expected to gain a significant share of the acute kidney injury disease treatment market.

North America has an increasing number of people suffering from kidney failure. The key reasons for it include alcoholic habits, diabetes, and increased blood pressure among the elderly which rises the risk for acute kidney failure in the region. According to CDC (Centre for Disease Control and Prevention), 37.3 million people have diabetes in the USA and 28.7 million people are diagnosed with it. Furthermore, binge drinking has harmful effects on health causing acute kidney failure and regular heavy drinking has further doubled the risk for chronic kidney disease which has increased the need for acute kidney treatment. Moreover, RRT is used increasingly used in the treatment of kidneys that replaces the waste filtering functions of the kidney.

COVID-19 Insights

COVID-19 had a significant impact on acute kidney injury disease treatment. The pandemic caused many issues in the body of which kidney problems were quite common. Many patients who were diabetic and had increased blood pressure witnessed increased risks of kidney failure. Furthermore, lack of oxygen caused kidneys to malfunction and increased blood clotting in the blood vessels in the kidney. Therefore, the need for fast acute kidney injury treatment increased. Additionally, in-home dialysis increased during the pandemic as a result of geographical restrictions.

Acute Kidney Injury (AKI) Disease Treatment Market Scope:


Report Metric Details
 Market Size Value in 2020  US$29.976 billion
 Market Size Value in 2027  US$34.596 billion
 Growth Rate  CAGR of 2.07% from 2020 to 2027
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Diagnosis, Type of RRT, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Exponential Biotherapies, Inc., NIKKISO AMERICA, INC., AM-Pharma, RenalGuard Solutions, Inc., Angion Biomedica Corp., AtoxBio, Sentien Biotechnologies, Inc., Baxter
 Customization Scope  Free report customization with purchase


Market Segments

  • By Diagnosis
    • Urine Tests
    • Blood Tests
    • Glomerular Filtration Rate (GFR)
    • Imaging tests
    • Kidney Biopsy
  • By Type of RRT
    • Continuous
    • Intermittent
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

The acute kidney injury disease treatment market is projected to reach a total market size of US$34.596 billion by 2027.
The global acute kidney injury disease treatment market is projected to grow at a CAGR of 2.07% during the forecast period.
Acute Kidney Injury (AKI) Disease Treatment Market was valued at US$29.976 billion in 2020.
An increase in the geriatric population is expected to boost the acute kidney injury disease treatment market.
North America is expected to hold a significant share of the acute kidney injury (AKI) disease treatment market.


1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation



2.1. Research Data

2.2. Assumptions



3.1. Research Highlights



4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. The threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis



5.1. Introduction

5.2. Urine tests

5.3. Blood Tests

5.4. Glomerular Filtration Rate (GFR)

5.5. Imaging Tests

5.6. Kidney Biopsy



6.1. Introduction

6.2. Continuous

6.3. Intermittent



7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. Germany

7.4.2. France

7.4.3. United Kingdom

7.4.4. Others

7.5. The Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Others

7.6. Asia Pacific

7.6.1. China

7.6.2. Japan

7.6.3. South Korea

7.6.4. India

7.6.5. Indonesia

7.6.6. Others



8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrative

8.3. Mergers, Acquisition, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix



9.1.  Exponential Biotherapies, Inc.


9.3. AM-Pharma

9.4. RenalGuard Solutions, Inc.

9.5. Angion Biomedica Corp.

9.6. AtoxBio

9.7. Sentien Biotechnologies, Inc.

9.8. Baxter

Exponential Biotherapies, Inc.



RenalGuard Solutions, Inc.

Angion Biomedica Corp.


Sentien Biotechnologies, Inc.